Alcobra Ltd fka ADHD

[keekee]

Cantor Fitzgerald maintained its "buy" rating and $16 price target on the stock today following the announcement.

"We have liked the reworked phase III MEASURE study, which has been a key component of our investment thesis," the firm said.

Any issues the FDA has with preclinical information "could be resolved," Cantor added.

[keekee]

Will attempt to add more today although there are two other great opportunities in my radar

[ClayTrader]

* * $ADHD Video Chart 09-29-16 * *

Link to Video - click here to watch the technical chart video

[ValueInvestor15]

Agree. Although Cantor and Oppenheimer downgraded today... good buying opportunity to load up!

[Lunacy_John Galt]

In at 2.05 and holding. If IBB bounces back tomorrow, this could really have a nice day!

[stanace27]

I could see it would break you don't stay up there for long especially consolidation that strongly.

[keekee]

Glad someone is on this board. I thought posting on it was a waste of time. But, here's a good stock that can make some real dough. Bough about 6600 at $2.13 barely an hour ago but will add more tomorrow.

[stanace27]

Flippers just doing what they do best

[keekee]

Amazed at these sellers. Haven't seen a more IGNORANT selling in 15 years of trading. But I loaded big at $2.13. So I am happy

[stocktrademan]

ADHD bearish 4.00

[Christie Mensch]

What a trainwreck!
Any catalysts coming in early 2016?

[etcetera]

(ll)

[ThetaTrader]

$ADHD possible cup and handle forming. Can get in now or wait for a break of 8 for better confirmation. See chart: http://stks.co/f1iS7

[stocktrademan]

$ADHD DD Notes ~ http://www.ddnotesmaker.com/ADHD

bullish
quick trade

$ADHD recent news/filings

## source: finance.yahoo.com

Fri, 19 Dec 2014 01:09:12 GMT ~ Nasdaq stocks posting largest percentage decreases

[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220242625--finance.html
*********************************************************

Wed, 17 Dec 2014 17:26:00 GMT ~ Alcobra Ltd. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

[Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the Southern District of New York against Alcobra Ltd.

read full: http://finance.yahoo.com/news/alcobra-ltd-shareholder-alert-former-172600400.html
*********************************************************

Wed, 17 Dec 2014 17:00:00 GMT ~ INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Alcobra Ltd. (ADHD) to Contact the Firm

[GlobeNewswire] - NEW YORK -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alcobra Ltd. ("Alcobra" or the "Company") of the January 19, 2015 deadline to seek the ...

read full: http://finance.yahoo.com/news/investor-alert-faruqi-faruqi-llp-170000211.html
*********************************************************

Tue, 16 Dec 2014 23:16:00 GMT ~ SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Alcobra Ltd. to Contact Brower Piven Before the January 19, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- ADHD

[GlobeNewswire] - STEVENSON, Md. -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern ...

read full: http://finance.yahoo.com/news/shareholder-alert-brower-piven-encourages-231600422.html
*********************************************************

Tue, 16 Dec 2014 21:52:00 GMT ~ ADHD SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Alcobra Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 19, 2015 -- ADHD

[GlobeNewswire] - NEW YORK -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Alcobra ...

read full: http://finance.yahoo.com/news/adhd-shareholder-alert-levi-korsinsky-215200056.html
*********************************************************


$ADHD charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ADHD company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ADHD/company-info
Ticker: $ADHD
OTC Market Place: Not Available
CIK code: not found
Company name: Alcobra Ltd.
Incorporated In:

Business Description:


$ADHD share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$ADHD extra dd links

Company name: Alcobra Ltd.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ADHD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ADHD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ADHD+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ADHD/news - http://finance.yahoo.com/q/h?s=ADHD+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ADHD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ADHD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ADHD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ADHD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Alcobra+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Alcobra+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Alcobra+Ltd.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ADHD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ADHD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ADHD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ADHD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ADHD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ADHD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ADHD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ADHD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ADHD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ADHD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ADHD+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ADHD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ADHD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ADHD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ADHD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ADHD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ADHD/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ADHD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ADHD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ADHD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ADHD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ADHD



$ADHD DD Notes ~ http://www.ddnotesmaker.com/ADHD

[TOXX]

Appears to be extremely oversold... good for a bounce to 5.00 next week??

[shankapotamus]

http://thebagholderdiaries.blogspot.com/2014/10/adhd-shareholders-swallowed-big-pill.html

[midastouch017]

Alcobra's Metadoxine trial fails to show efficacy vs. placebo, share down AH • 5:30 PM
Douglas W. House, SA News Ed...
Lightly-traded nano cap Alcobra (ADHD +10.9%) slumps 13% AH on higher-than-average volume in response to a presentation of results from a Phase 2b clinical trial evaluating Metadoxine (vitamin B6 and L-PGA) for the treatment of attention deficit/hyperactivity disorder given by Dr. Lenard Adler at the American Academy of Child & Adolescent Psychiatry Meeting in San Diego.
On Slide 26, the graph shows that Metadoxine failed to demonstrate statistically significant efficacy compared to placebo at week six (p=0.136). This was the study's primary endpoint.

[Wildbilly]

A little green PM with more vol.

than yesterdays regular session.

[willmakeitrain]

That wasn't the reason---why don't u actually answer the question

[conix]

Company will have to raise more capital. More dilution coming

[Wildbilly]

edit



.

[ClayTrader]

* * $ADHD Video Chart 10-06-14 * *

Link to Video - click here to watch the technical chart video

[Stock_Gambit]

Why is this nose diving so hard. They just need to retest right?

[conix]

ADHD chart

[Babbu1]

h

[TheFinalCD]

looks like it may bounce more @ the open

lets see

[willmakeitrain]

Yah it's sad..what u thinkin?...4-6?

[TheFinalCD]

http://seekingalpha.com/news/2015965-alcobra-plummets-on-phase-3-trial-results

GOOD INSIGHT:


http://seekingalpha.com/article/2532115-overpriced-expectations-alcobra-will-get-to-second-base-but-no-home-run-options-are-mispriced-for-an-unlikely-event

[willmakeitrain]

Except premarket-not liking it?...wow8.20!

[midastouch017]

Alcobra Announces Topline Results From Phase III Study of MDX in Adult ADHD

Company to hold a conference call Monday, October 6, 2014 at 8:30am EDT

TEL AVIV, Israel, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced topline results from a Phase III study of Metadoxine Extended Release (MDX) in adults with ADHD. In a modified Intent To Treat (mITT) population (n=293), MDX demonstrated a statistically significant improvement in ADHD symptoms compared to placebo as measured by the Conner's Adult ADHD Rating Scale (CAARS-INV) (p<0.03). The mITT population was derived by a post hoc exclusion of four subjects with extreme placebo responses (The ITT analysis before exclusion yielded a positive trend, p=0.15; n=297).

"This is a key milestone for Alcobra," said Dr. Yaron Daniely, Alcobra's President and Chief Executive Officer. "We are encouraged by these findings, as they build upon our Phase II studies showing that MDX significantly improved symptoms of ADHD without many of the safety and tolerability issues commonly associated with currently available ADHD medications. We look forward to completing the full analysis on the secondary endpoints in the study and reporting the complete data set in the near future."

The 300-patient, randomized, placebo-controlled study was conducted at 18 sites in the United States and 2 in Israel. Approximately 70 percent of patients were enrolled in the U.S., and patients were nearly evenly split between men and women. Patients were randomized to receive either 1400 mg of MDX or placebo over 6 weeks. The primary endpoint was the CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms, which has been utilized in registration studies for other approved ADHD drugs.

In the mITT analysis, there was a mean change on the CAARS-INV from baseline to the final visit of 11.6 in the MDX treated group as compared with a mean change of 8.7 in the placebo treated group (p<0.03). MDX also showed a statistically significant impact on the inattention subscale of the CAARS-INV (p<0.05). Patients with both predominately inattentive (PI) ADHD and combined type (CT) ADHD subtypes appeared to benefit similarly in this trial.

"We conducted the mITT analysis after observing the disproportional effect of a few extremely large placebo responses which were inconsistent with what has been reported in previous ADHD trials of MDX or other agents," said Dr. Jonathan Rubin, Alcobra's Chief Medical Officer. "We plan to take the complete findings of this and other MDX studies to the FDA to determine the next steps on the path to potential regulatory approval for MDX."

MDX was well tolerated during the trial. The number of patients reporting adverse events was similar between the MDX and placebo groups with no drug-related serious adverse events reported. The most common adverse events seen in the study were headache (15.1% in MDX group vs. 12.3% in placebo group), nausea (8.6% vs. 6.2%), and fatigue (7.2% vs. 8.2%).

Detailed results of the study will be made available at various scientific and medical conferences in the coming weeks, as well as in peer-reviewed publications. Additional advanced clinical studies of MDX in adolescents with ADHD, as well as in adolescents and adults with Fragile X Syndrome are currently actively enrolling patients. These studies are expected to be completed by the end of 2014.

Conference Call

Monday, October 6 2014, @ 8:30am Eastern Time/5:30am Pacific Time
Domestic: 855-469-0611
International: 484-756-4341
Conference ID: 15517950
Webcast: http://www.media-server.com/m/p/bsr2eo4r

[maytepper]

$ADHD Alcobra: Does The Pre-Data Selloff Imply A Failed Phase 3? Roth Capital Comments http://www.smarteranalyst.com/2014/10/02/alcobra-pre-data-selloff-imply-failed-phase-3-roth-capital-comments/

[midastouch017]

Bearish behavior for Alcobra • 4:12 PM
Douglas W. House, SA News Ed...
Thinly-traded micro cap Alcobra (ADHD -18.3%) plummets on a 4x surge in volume. The drop takes out the recent up move which started on September 16. Shares peaked at $21.53 on September 23 representing 34% rise from the September 11 low of $16.06.
On September 22, the company announced that it had completed all patient follow-up visits in its Phase 3 trial of Metadoxine Extended Release. The top-line analysis is due in another week.
If the down trend continues, then it is a clear signal that somebody knows something and it ain't positive. Longs beware.

[traderzer0]

Get ready.

[Wildbilly]

Seemed fairly predictable to me,

I guess some were selling on the news last week.

[maytepper]

$ADHD Roth Capital Reiterates Buy On Alcobra Following The Completion Of Phase III Clinical Trial of MDX http://www.smarteranalyst.com/2014/09/22/roth-capital-reiterates-buy-alcobra-following-completion-phase-iii-clinical-trial-mdx/

[RealGenius]

Wow, nice move today. Probably sell at $21 for me.

[RealGenius]

This week is go time. Lets get over $20.

[Wildbilly]

Parents aren't concerned with ADHD any more?

Alcobra Ltd. (ADHD) Expects Topline MDX Phase III Clinical Trial Data in Two Weeks

September 19, 2014 4:35 PM EDT

Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that all scheduled follow-up visits have been completed for patients enrolled in the company's Phase III clinical trial of Metadoxine Extended Release (MDX) in adult ADHD patients.

"Completion of this Phase III clinical trial is a major milestone in the development of MDX, as we are one step closer to a potential new treatment alternative for Adult ADHD," said Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra. "We currently anticipate completing data verification in this multi-center trial, database lock and topline statistical analysis in approximately two weeks. We look forward to unblinding the data and announcing the results."

The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks followed by a 2-week safety follow-up and preceded by a 2-week screening period. The primary endpoint measure is the Conners' Adult ADHD Rating Scale (CAARS-INV), a widely accepted clinical measure of the presence and severity of ADHD symptoms, and the same endpoint utilized in the company's successful Phase IIb study. Secondary endpoints include the computerized TOVA (Test of Variables of Attention), which was also used in the previous Phase II studies, as well as safety assessments and additional exploratory endpoints.

http://www.streetinsider.com/Corporate+News/Alcobra+Ltd.+(ADHD)+Expects+Topline+MDX+Phase+III+Clinical+Trial+Data+in+Two+Weeks/9847867.html








.

[jeks108]

bullish engulfing candle today. Looks to be the start of the next uptrend

[maytepper]

$ADHD Roth Capital Provides Input Into Alcobra’s Fragile X Program; Keeps $40 Price Target http://www.smarteranalyst.com/2014/09/15/roth-capital-provides-input-into-alcobras-fragile-x-program-keeps-40-price-target/

[jeks108]

Great find here. ADHD chart has some nice technical upswings and is currently in a tight consolidation. I expect a breakout soon. I am also excited fundamentally with the trials coming up. We should have great results by the end of the year! Great results = great stock prices!

[midastouch017]

Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Adolescents With ADHD

TEL AVIV, Israel, Sept. 2, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that the first patient has been enrolled in a Phase IIb study of MDX in adolescents with ADHD. The trial is expected to complete enrollment and report topline data by the end of 2014.

The Phase IIb trial is a multi-center, randomized, double-blind, fixed dose study designed to evaluate the safety and tolerability of MDX in up to 82 adolescents (aged 13-17) with predominantly inattentive ADHD (PI-ADHD). The primary endpoint will be safety, tolerability and pharmacokinetics. Secondary endpoints include change in efficacy measures such as TOVA (Test of Variables of Attention), Wechsler Intelligence Scale for Children (WISC-IV) subtests, and working memory and processing speed. ClinicalTrials.gov Identifier: NCT02189772

[midastouch017]

Alcobra Releases New Neuroimaging Data Supporting Pro-Cognitive Effects of MDX

TEL AVIV, Israel, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today released new imaging data on brain activity associated with MDX treatment.

Alcobra released topline results from a pharmacological MRI study designed to evaluate the regions of the brain that are modulated by MDX. The study evaluated brain response to a single administration of Metadoxine in rats. The experiment included 3 treatment arms: a placebo group, a low-dose group (corresponding approximately to the 700mg MDX dose in humans), and a high-dose group (corresponding approximately to the 1400mg MDX dose in humans). Neuronal activity was examined by evaluating Blood Oxygen Level Dependent (BOLD) MRI imaging, which measures brain oxygen levels that are related to changes in brain nerve cell activity. BOLD phMRI was employed to study 170 different areas of the brain following placebo or drug administration.

The results showed that Metadoxine produced a significant, dose-dependent decrease in BOLD signal in highly selective regions of the brain including the prefrontal cortex and showed a statistically significant increase in BOLD response in brain regions including the central nucleus of the amygdala and the lateral hypothalamus. In addition, none of the mesolimbic dopamine system brain regions (such as the nucleus accumbens), known to be involved in the reinforcing effects of scheduled drugs, were significantly affected by Metadoxine at any dose level, which is consistent with previously presented data.

"Metadoxine produced a specific and extensive effect in brain areas related to executive function, learning and memory, motivation, information integration and processing, attention and cognition," said Dr. Jonathan Rubin, Chief Medical Officer of Alcobra. "A functional decrease in these neuronal circuits mediated by MDX may help ADHD patients filter unnecessary sensory stimuli. These findings also confirm and extend previous data demonstrating a novel monoamine-independent mechanism of action of Metadoxine characterized by GABAergic inhibitory transmission modulation."

Dr. Jonathan Rubin will present the results during the company's second quarter financial results and operational update call and webcast on Monday, August 11.

[midastouch017]

Alcobra Completes Patient Recruitment in Phase III Clinical Trial of MDX in Adult ADHD
GlobeNewswire Alcobra Ltd.

TEL AVIV, Israel, July 14, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that recruitment of patients has been completed in the Company's Phase III clinical trial of Metadoxine Extended Release (MDX) in adult ADHD patients.

"I would like to thank all the patients who participated in the trial, as well as the professional work by our investigators who quickly and rigorously enrolled patients in less than four months," said Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra. "We look forward to all patients completing the study protocol, and reporting the topline results later this quarter."

The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks following a 2-week screening period. The primary endpoint is the Conners' Adult ADHD Rating Scale (CAARS-INV), a widely accepted clinical measure of the presence and severity of ADHD symptoms. Secondary endpoints include the computerized TOVA (Test of Variables of Attention), which was also used in the previous Phase 2 studies, as well as safety assessments and additional exploratory endpoints.

"We are pleased we have reached this important milestone in the execution of the trial," said Dr. Richard Weisler, Principal Investigator of the study, adjunct professor of psychiatry at the University of North Carolina School of Medicine and adjunct associate professor of psychiatry at Duke University Medical Center. "There remain substantially unmet needs in the management of adult ADHD and this trial, when completed, will provide important clinical information to the medical community."

As previously announced, Alcobra will host an Investor Forum on Tuesday, July 15, 2014 from 8am-9:30am Eastern Time in New York City. Management will provide an update on the ongoing development program for MDX. Dr. Craig Surman, MD, an expert in the management of adult ADHD will offer insights into the diagnosis and management of adult ADHD, and current therapeutic options and unmet medical needs in ADHD. Alcobra's executive management team will provide an evidence-based overview of the commercial potential for its lead product, Metadoxine Extended Release (MDX), in ADHD based on recently completed primary and secondary research and analysis.

The presentations, followed by a question-and-answer session, will be webcast live beginning at 8am Eastern Time. The webcast and accompanying presentation materials will be accessible live and archived on the Investor Relations section of Alcobra's website at www.alcobra-pharma.com.

[stocktrademan]

Alcobra Ltd. [$ADHD] due diligence

bullish weekly trade 30-50% on margin



$ADHD

DD Notes ~ http://www.ddnotesmaker.com/ADHD

##### recent news/filings ~ source: finance.yahoo.com

Mon, 07 Jul 2014 12:00:00 GMT ~ Alcobra to Host Investor Forum and Webcast on July 15 in New York City
[GlobeNewswire] - TEL AVIV, Israel -- Alcobra Ltd. , an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity ...
read full: http://finance.yahoo.com/news/alcobra-host-investor-forum-webcast-120000461.html
*********************************************************

Thu, 03 Jul 2014 21:16:00 GMT ~ Nasdaq stocks posting largest volume increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-volume-220410239--finance.html
*********************************************************

Thu, 03 Jul 2014 12:16:03 GMT ~ Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session
read full: http://finance.yahoo.com/news/alcobra-adhd-jumps-stock-adds-121603764.html
*********************************************************

Wed, 02 Jul 2014 11:19:23 GMT ~ Alcobra shares should be bought ahead of data, says Stifel
read full: http://finance.yahoo.com/news/alcobra-shares-bought-ahead-data-111923499.html
*********************************************************

Thu, 26 Jun 2014 13:13:18 GMT ~ Coverage initiated on Alcobra Pharma by WBB Securities
read full: http://finance.yahoo.com/q/ud?s=ADHD
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ADHD/company-info
Ticker: $ADHD
OTC Market Place: Not Available
CIK code: not found
Company name: Alcobra Ltd.
Incorporated In:

##### extra dd links

Latest filings: http://www.otcmarkets.com/stock/ADHD/filings
Latest financials: http://www.otcmarkets.com/stock/ADHD/financials
Latest news: http://www.otcmarkets.com/stock/ADHD/news - http://finance.yahoo.com/q/h?s=ADHD+Headlines

Major holdings: http://data.cnbc.com/quotes/ADHD/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ADHD+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ADHD.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ADHD

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=ADHD&search=search

DTCC: http://search2.dtcc.com/?q=Alcobra+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Alcobra+Ltd.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Alcobra+Ltd.&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/ADHD/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ADHD/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ADHD/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ADHD+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ADHD+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ADHD+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ADHD+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ADHD+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ADHD+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ADHD
Balance Sheet: http://finance.yahoo.com/q/bs?s=ADHD
Cash Flow: http://finance.yahoo.com/q/cf?s=ADHD+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ADHD
Bloomberg: http://www.bloomberg.com/quote/ADHD:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ADHD
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ADHD
Barchart: http://www.barchart.com/quotes/stocks/ADHD
OTC Short Report: http://otcshortreport.com/index.php?index=ADHD
Investopedia: http://www.investopedia.com/markets/stocks/ADHD/?wa=0

http://www.pennystocktweets.com/stocks/profile/ADHD

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/ADHD
a11k

[midastouch017]

Alcobra Ltd. to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference
Tuesday 27 May 2014

Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City.
Jefferies 2014 Global Healthcare Conference Presentation Details
Date: Tuesday, June 3, 2014
Time: 8:00am Eastern
Location: Grand Hyatt Hotel in New York City
Webcast: http://wsw.com/webcast/jeff82/adhd

[traderzer0]

Anybody here? Chance to make ~100% gains after Phase 3 data in September. Story here is ridiculously beautiful in terms of market potential.

[midastouch017]

Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Frag...

Thursday 8 May 2014

Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that FDA has approved the protocol for the Company's planned Phase IIb clinical trial of MDX for the treatment of Fragile X Syndrome. The trial is expected to begin enrolling patients shortly.
The Phase IIb study will be a multi-center, randomized, placebo-controlled study, conducted primarily in the US, and is supported by positive data collected from multiple earlier pre-clinical studies. Results from these pre-clinical studies demonstrated significant improvement in behavioral and cognitive outcomes based on evaluations of memory, learning, and social interaction. In a validated mouse model of Fragile X Syndrome, metadoxine treatment was shown to result in improved levels of certain Fragile X-associated blood and brain biological markers that may have a role in learning and memory, while simultaneously reducing the number of immature brain connections and levels of abnormally increased protein. The FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome in December 2013.

"Given the lack of FDA approved therapies, there is a substantial unmet need for treatment options for Fragile X Syndrome," said Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra. "We are pleased that the FDA has approved the protocol for our Phase IIb study, and we expect it to provide important insights into the potential role of MDX in this and related conditions."

About Fragile X Syndrome

Fragile X syndrome (FXS) is a genetic condition that causes intellectual disability, behavioral and learning challenges and various physical characteristics. Behavioral characteristics can include ADHD, autism and autistic behaviors, social anxiety, stereotypic movements, poor eye contact, sensory disorders and increased risk for aggression. Fragile X Syndrome is the leading known genetic cause of autism, accounting for about 2-5% of cases. Fragile X Syndrome represents an unmet medical need and a rare disease, as defined by the Orphan Drug Act. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately one in 4,000 males and one in 8,000 females have Fragile X Syndrome. The FDA has not approved any drugs specifically for the treatment of Fragile X Syndrome or its symptoms.

[midastouch017]

Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly...
Monday 5 May 2014

MDX produced statistically significant improvement (p < 0.01) on the primary endpoint compared to placebo
MDX was superior to placebo after a single dose while demonstrating a safety profile comparable to placebo
Second placebo-controlled Phase II study in adults with ADHD to demonstrate the efficacy and tolerability of MDX

Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced the presentation of data from a successful Phase IIb study of its proprietary drug candidate MDX (Metadoxine Extended Release) in adults with Predominantly Inattentive ADHD (PI-ADHD) at the 167th Annual Meeting of the American Psychiatric Association (APA).1

"Results from this study showed that MDX provided significant benefit for adults with PI-ADHD after one dose and was as well tolerated as placebo, suggesting that it could eventually offer an attractive non-scheduled treatment option," said Iris Manor, M.D., senior lecturer and director of the ADHD unit at Geha Mental Health Center. "Evidence of a preferential effect of MDX in this patient population further distinguishes it from conventional stimulant and non-stimulant medications, and we are very excited to share these data with the ADHD treatment community through this important scientific forum."

This Phase IIb randomized, double-blind, placebo-controlled, cross-over, single center study enrolled 36 adult patients (18 to 55 years old) with diagnosed PI-ADHD. Eligible subjects were randomly assigned in a 1:1:1 ratio to one of three treatment sequences that varied the order of investigational product administration. In each sequence, subjects received a single dose, approximately one week apart, of MDX 1400 mg, MDX 700 mg, and placebo. The primary endpoint of the study was the mean change from baseline of the Test of Variable of Attention (TOVA®) ADHD Score. The TOVA is a computerized continuous performance test (CPT) that provides information about an individual's sustained attention, speed and consistency of responding, and behavioral self-regulation.

As previously announced, the intent-to-treat analysis of the primary endpoint demonstrated a statistically significant change from baseline for a single dose of MDX 1400 mg compared with placebo on the TOVA ADHD Score (mean change 2.0, SD 4.2, p = 0.009). The study also demonstrated a statistically significant change from baseline for MDX 1400 mg compared to placebo on the TOVA sub-score of response time variability (mean change 7.9, SD 19.2, p = 0.022), a sub-score correlated with attention and cognition. In addition, the percentage of responders following a single dose of MDX 1400 mg was significantly greater compared with placebo. There were no significant differences observed between the MDX 700 mg dose and placebo in the primary or secondary efficacy endpoints. Between the two doses of MDX, the 1400 mg dose demonstrated significantly greater improvements (p < .05) than the 700 mg dose on most endpoints.

There were no serious adverse events or any meaningful differences in adverse events profiles between the drug and placebo groups. The most common treatment emergent adverse events (TEAEs) during the active treatment period were fatigue and headache. All adverse events were mild except for three reports of moderate headache. No clinically significant abnormalities in laboratory values, vital sign measurements, ECG parameters, or findings at clinical examination were observed.

Based on these results and the successful outcome of a prior Phase II placebo-controlled study of MDX, Alcobra is moving forward with a Phase III trial in adults with ADHD. The study is expected to be completed in the second half of 2014.

[midastouch017]

Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fr...
Thursday 10 April 2014

Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it has submitted a protocol to the FDA for a Phase IIb clinical trial for its MDX product candidate for the treatment of patients with Fragile X Syndrome.
The planned Phase IIb MDX clinical trial will be a multi-center, randomized, placebo-controlled study, conducted primarily in the US. The protocol submission is under an IND and is supported by strong, positive data collected from multiple earlier pre-clinical trials on metadoxine. Results from these studies demonstrated significant improvement in behavioral and cognitive outcomes based on evaluations of memory, learning, and social interaction. Furthermore, in a validated mouse model of Fragile X Syndrome, metadoxine treatment was shown to result in improved levels of certain Fragile X-associated blood and brain biological markers that may have a role in learning and memory, while simultaneously reducing the number of immature brain connections and levels of abnormally increased protein. In December 2013, the FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome.

Elizabeth M. Berry-Kravis, MD, PhD, Professor of Biochemistry, Neurological Sciences and Pediatrics at Rush University Medical Center in Chicago, Illinois and Principal Investigator in this study commented, "Patients with Fragile X Syndrome currently have limited treatment options, with no FDA approved medications. The positive findings reported from the preclinical studies, together with information that is known on the mechanism of action of metadoxine, suggest that MDX may be helpful in treating cognitive symptoms in these patients. This Phase IIb study should provide us with important insights into the potential role of MDX in this condition."

About Fragile X Syndrome

Fragile X syndrome (FXS) is a genetic condition that causes intellectual disability, behavioral and learning challenges and various physical characteristics. Behavioral characteristics can include ADHD, autism and autistic behaviors, social anxiety, stereotypic movements, poor eye contact, sensory disorders and increased risk for aggression. Fragile X Syndrome is the leading known genetic cause of autism, accounting for about 2-5% of cases. Fragile X Syndrome represents an unmet medical need and a rare disease, as defined by the Orphan Drug Act. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately one in 4,000 males and one in 8,000 females have Fragile X Syndrome. The FDA has not approved any drugs specifically for the treatment of Fragile X Syndrome or its symptoms.